CAMP4 THERAPEUTICS CORP (CAMP) Stock News

USA - NASDAQ:CAMP - US13463J1016 - Common Stock

3.79 USD

+0.25 (+7.06%)

Last: 10/9/2025, 8:58:15 PM

3.7 USD

-0.09 (-2.37%)

Pre-Market: 10/10/2025, 4:46:14 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CAMP Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: CAMP4 Therapeutics

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

9 days ago - By: CAMP4 Therapeutics

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

a month ago - By: Benzinga - Mentions: KEQU BLRX VNRX RNA ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

2 months ago - By: The Motley Fool

Camp4 Reports Q2 Revenue Beats Estimates

6 months ago - By: Benzinga - Mentions: GNFT EWTX

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

a month ago - By: CAMP4 Therapeutics

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

a month ago - By: CAMP4 Therapeutics

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

2 months ago - By: CAMP4 Therapeutics

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

2 months ago - By: CAMP4 Therapeutics

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

5 months ago - By: CAMP4 Therapeutics

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American

5 months ago - By: CAMP4 Therapeutics

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American

5 months ago - By: CAMP4 Therapeutics

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

5 months ago - By: CAMP4 Therapeutics

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

5 months ago - By: CAMP4 Therapeutics

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

5 months ago - By: CAMP4 Therapeutics

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

7 months ago - By: CAMP4 Therapeutics

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

7 months ago - By: CAMP4 Therapeutics

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

7 months ago - By: CAMP4 Therapeutics

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

7 months ago - By: CAMP4 Therapeutics

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

8 months ago - By: CAMP4 Therapeutics

CAMP4 to Participate in Upcoming Investor Conferences

8 months ago - By: CAMP4 Therapeutics

CAMP4 to Participate in Upcoming Investor Conferences

9 months ago - By: CAMP4 Therapeutics

CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference

9 months ago - By: CAMP4 Therapeutics

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

9 months ago - By: CAMP4 Therapeutics

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

10 months ago - By: CAMP4 Therapeutics - Mentions: KRRO

CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

10 months ago - By: CAMP4 Therapeutics

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference